Tag: ROADSTER 3

Silk Road Medical Announces Post Approval Study for the Treatment of Standard Surgical Risk Patients using TCAR

SUNNYVALE, Calif., June 15, 2022 (GLOBE NEWSWIRE) —  Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced a prospective study to evaluate the TCAR® system in the treatment of standard surgical risk patients with carotid artery disease. The post-market study, called ROADSTER 3, will […]